UPDATE: NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19) (NOT-OD-20-091)
National Institutes of Health

Notice of Early Expiration of Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV), NOT-AI-20-030 (NOT-AI-20-040)
National Institute of Allergy and Infectious Diseases
National Institute of General Medical Sciences

FDA - Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19 (NOT-FD-20-019)
Food and Drug Administration

Notice of 2nd deadline extension for the 2020 Application Due Date for PAR-20-091 “Revision Applications - FSMA Human Foods Preventive Controls Implementation Expansion Supplement to RFA-FD-18-001 (U18 Clinical Trials Not Allowed)” (NOT-FD-20-021)
Food and Drug Administration

Notice of Transfer of The National Children's Study (NCS) Archive Materials to the NICHD Data and Specimen Hub (DASH) (NOT-HD-20-010)
Eunice Kennedy Shriver National Institute of Child Health and Human Development

National Heart, Lung, and Blood Institute (NHLBI) Announces Big Data Analysis Challenge: Creating New Paradigms for Heart Failure Research (NOT-HL-20-758)
National Heart, Lung, and Blood Institute

Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19 (NOT-HS-20-007)
Agency for Healthcare Research and Quality
  Agency for Healthcare Research and Quality

• Request for Information (RFI): Inviting Comments on the Establishment and Implementation of a Standard Unit Dose of Delta-9-tetrahydrocannabinol (THC) for Cannabis Research (NOT-DA-20-043)
  National Institute on Drug Abuse

Notice of Changes to Funding Opportunities

• Notice to Extend the Submission Period to the National Cancer Institute (NCI) for PA-18-906, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) (NOT-CA-20-041)
  National Cancer Institute

• Notice of NIBIB's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)" (NOT-EB-20-004)
  National Institute of Biomedical Imaging and Bioengineering

• Notice to correct Section II - Award Information for RFA-FD-20-030 - "Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional." (NOT-FD-20-018)
  Food and Drug Administration

• Notice of Change to the 2020 Application Due Date and New Scored Review Criteria for Overall and Admin Components for PAR-20-105 titled "Laboratory Flexible Funding Model (LFFM) (U19) Clinical Trials Not Allowed" (NOT-FD-20-020)
  Food and Drug Administration

• Notice of Change of Receipt Date for Mendelian Genomics Research Centers (RFA-HG-20-007) and Mendelian Genomics Data Coordinating Center (RFA-HG-20-008) (NOT-HG-20-033)
  National Human Genome Research Institute

• Notice of NIMHD Withdrawal from Participation in PA-19-053, "NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)" (NOT-MD-20-015)
  National Institute on Minority Health and Health Disparities

• Notice of NIMHD Withdrawal from Participation in PA-19-054, "NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)" (NOT-MD-20-016)
  National Institute on Minority Health and Health Disparities
- Notice of NIMHD Withdrawal from Participation in PA-19-092, "NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)"
  (NOT-MD-20-017)
  National Institute on Minority Health and Health Disparities

- Notice of Change to Key Dates for PAR-17-480 "NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44)"
  (NOT-NS-20-043)
  National Institute of Neurological Disorders and Stroke

- Notice of Change: Extension to end date for NOT-OD-20-059 (RFI: Scientific Priorities for Behavioral and Social Science Research at NIH)
  (NOT-OD-20-092)
  Office of Behavioral and Social Sciences Research

Notices of Special Interest

- Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
  (NOT-AI-20-031)
  National Institute of Allergy and Infectious Diseases

- Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
  (NOT-AI-20-034)
  National Institute of Allergy and Infectious Diseases

- Notice of Special Interest (NOSI): Administrative Supplements for the Use of Existing Body Composition Data to Understand Treatment-Related Outcomes in Clinical Trials and Observational Studies
  (NOT-CA-20-036)
  National Cancer Institute

- Notice of Special Interest (NOSI): Administrative Supplements for Understanding Aging Trajectories Among Cancer Survivors
  (NOT-CA-20-037)
  National Cancer Institute

- Notice of Special Interest (NOSI): Administrative Supplements for Exploring the Intersection of Tobacco and Alcohol Use Behaviors for Cancer Control
  (NOT-CA-20-039)
  National Cancer Institute

- Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes
  (NOT-DA-20-018)
  National Institute on Drug Abuse

- Notice of Special Interest (NOSI): Sleep and Substance Use Disorders
  (NOT-DA-20-021)
  National Institute on Drug Abuse
• Notice of Special Interest (NOSI): Research Training and Career Development Awards to Support Individuals Pursuing Research Focused on Developing Treatments for Substance Use Disorders and the Associated Medical Consequences of these Disorders (NOT-DA-20-037)
  National Institute on Drug Abuse

• Notice of Special Interest: Hurricane Harvey Administrative Supplements (NOT-ES-20-012)
  National Institute of Environmental Health Sciences

• Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed) (NOT-ES-20-014)
  National Institute of Environmental Health Sciences

• Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
  National Institute of General Medical Sciences

• Notice of Special Interest (NOSI): Availability of Administrative Supplements to Advance Safe and Effective Therapeutics in Pregnant and Lactating Women and Children (NOT-HD-20-003)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Human Genome Research Institute
  National Institute of General Medical Sciences
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke

• Notice of Special Interest (NOSI): Availability of Administrative Supplements for Providing Research Experiences for Data Scientists (NOT-HG-20-029)
  National Human Genome Research Institute

• NHLBI and NIDA Announce Availability of Administrative Supplements for HEAL Awardees to Address Sleep Impairments in OUD Treatment Response and Recovery Outcomes (NOT-HL-20-746)
  National Heart, Lung, and Blood Institute
  National Institute on Drug Abuse

• Notice of Special Interest: Health Services Research on Minority Health and Health Disparities (R01 - Clinical Trial Optional) (NOT-MD-20-011)
  National Institute on Minority Health and Health Disparities
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  Office of Behavioral and Social Sciences Research
• **Notice of Special Interest (NOSI): Strengthening the HIV Prevention Continuum**
  (NOT-MH-20-019)
  National Institute of Mental Health

• **Notice of Special Interest (NOSI): Administrative Supplements to NINR Predoctoral Training Grants to Enhancing Training in Genomics**
  (NOT-NR-20-003)
  National Institute of Nursing Research
  National Human Genome Research Institute

• **Notice of Special Interest (NOSI): Research to Improve the Interpretation of Patient-Reported Outcomes at the Individual Patient Level for Use in Clinical Practice**
  (NOT-OD-20-079)
  Office of Behavioral and Social Sciences Research
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Human Genome Research Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Office of Disease Prevention
  Office of Research on Women's Health

• **Notice of Special Interest: Research to Advance the Understanding of Tobacco Product Pharmacokinetic Research**
  (NOT-OD-20-081)
  Office of Disease Prevention
  U.S. Food and Drug Administration, Center for Tobacco Products
  Food and Drug Administration
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences

• **Notice of Special Interest: Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)**
  (NOT-OD-20-084)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

• **Notice of Special Interest: Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)**
  (NOT-OD-20-085)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

• **Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need**
Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

National Center for Advancing Translational Sciences

Funding Opportunities

- Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)
  (PA-20-144)
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

- Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
  (PA-20-145)
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

- NIDA Small Research Grant Program (R03 Clinical Trial Required)
  (PA-20-146)
  National Institute on Drug Abuse
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 16, 2020.

- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01 Clinical Trial Not Allowed)
  (PAR-20-147)
  National Institute on Drug Abuse
  Application Receipt Date(s): October 13, 2020, March 15, 2021, October 13, 2021, March 15, 2022, October 13, 2022, March 15, 2023

- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21 Clinical Trial Not Allowed)
  (PAR-20-148)
  National Institute on Drug Abuse
  Application Receipt Date(s): October 13, 2020, March 15, 2021, October 13, 2021, March 15, 2022, October 13, 2022, March 15, 2023
  Standard dates apply. The first standard due date for this FOA is October 5, 2020

- NIMHD Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)
  (PAR-20-150)
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 16, 2020.

- Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
• **Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed)**
  (RFA-AI-20-024)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

• **Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)**
  (RFA-DA-21-005)
  National Institute on Drug Abuse
  Application Receipt Date(s): July 14, 2020

• **Special Topic Research Education Course: Exploring Auditory and Vestibular Biology (R25 - Clinical Trial Not Allowed)**
  (RFA-DC-20-001)
  National Institute on Deafness and Other Communication Disorders
  Application Receipt Date(s): June 26, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

• **Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)**
  (RFA-ES-20-009)
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): June 18, 2020

• **Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry Centers (U01 Clinical Trial Not Allowed)**
  (RFA-HG-20-001)
  National Human Genome Research Institute
  National Cancer Institute
  Office of Research on Women's Health
  Application Receipt Date(s): June 23, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

• **Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry Coordinating Center (U01 Clinical Trial Not Allowed)**
  (RFA-HG-20-002)
  National Human Genome Research Institute
  Application Receipt Date(s): June 23, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to
apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see https://grants.nih.gov/grants/guide/rss_info.htm for details.

To UnSubscribe from the NIH Guide Weekly TOC LISTSERV, follow the instructions at https://grants.nih.gov/grants/guide/listserv.htm